AVITA Medical, Inc. (RCEL) 10-Year Financial Performance & Capital Metrics

RCEL • • Industrial / General

HealthcareMedical DevicesAesthetic & Reconstructive DevicesBreast Implants & Aesthetic Devices

AboutAVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.Show more

Revenue $64M +28.1%
EBITDA -$55M -32.0%
Net Income -$62M -74.8%
EPS (Diluted) -2.39 -70.7%
Gross Margin 85.85% +1.6%
EBITDA Margin -86.33% -3.0%
Operating Margin -88.08% -3.5%
Net Margin -96.26% -36.4%
ROE -230.96% -336.7%
ROIC -80.25% -71.6%
Debt/Equity 10.22 +1082.3%
Interest Coverage -10.56 +71.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 35.1%

✗Weaknesses

✗High debt to equity ratio of 10.2x
✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 10 (bottom 10%)
✗Trading more than 30% below 52-week high
✗Expensive at 19.9x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y51.85%

5Y35.12%

3Y24.84%

TTM38.32%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-3.5%

EPS CAGR

10Y-

5Y-

3Y-

TTM7.81%

ROCE

10Y Avg-98.19%

5Y Avg-39.13%

3Y Avg-48.6%

Latest-71.64%

Peer Comparison

Breast Implants & Aesthetic Devices

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INMDInMode Ltd.	888.09M	14.05	6.24	-19.76%	41.04%	22.89%	14.86%	0.01
RCELAVITA Medical, Inc.	105.51M	3.46	-1.45	28.14%	-68.87%	-230.96%		10.22
SSKNSTRATA Skin Sciences, Inc.	7.6M	1.29	-4.96	0.61%	-35.64%	-8.4%		3.31
ESTAEstablishment Labs Holdings Inc.	1.92B	65.96	-21.99	0.53%	-43.45%	-5.07%		4.24

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1M	1.18M	1.26M	5.47M	14.26M	29.23M	33.02M	34.42M	50.14M	64.25M
Revenue Growth %	0.02%	0.18%	0.06%	3.36%	1.61%	1.05%	0.13%	0.04%	0.46%	0.28%
Cost of Goods Sold+	401.57K	505.64K	737.7K	1.27M	2.97M	5.95M	6.1M	6.04M	7.78M	9.09M
COGS % of Revenue	0.4%	0.43%	0.59%	0.23%	0.21%	0.2%	0.18%	0.18%	0.16%	0.14%
Gross Profit+	600.44K	675K	517.47K	4.2M	11.29M	23.28M	26.92M	28.38M	42.36M	55.16M
Gross Margin %	0.6%	0.57%	0.41%	0.77%	0.79%	0.8%	0.82%	0.82%	0.84%	0.86%
Gross Profit Growth %	-0.14%	0.12%	-0.23%	7.12%	1.69%	1.06%	0.16%	0.05%	0.49%	0.3%
Operating Expenses+	11.95M	13.35M	19.15M	29.73M	53.97M	49.82M	52.04M	55.88M	85.02M	111.75M
OpEx % of Revenue	11.93%	11.3%	15.25%	5.43%	3.78%	1.7%	1.58%	1.62%	1.7%	1.74%
Selling, General & Admin	10.93M	13.9M	21.21M	27.65M	48.73M	37.06M	37.21M	45.24M	65.63M	91.39M
SG&A % of Revenue	10.91%	11.78%	16.9%	5.05%	3.42%	1.27%	1.13%	1.31%	1.31%	1.42%
Research & Development	3.46M	6.27M	8.45M	8M	9.16M	14.82M	15.67M	13.86M	20.82M	20.36M
R&D % of Revenue	3.45%	5.31%	6.74%	1.46%	0.64%	0.51%	0.47%	0.4%	0.42%	0.32%
Other Operating Expenses	0	0	0	-5.92M	-3.93M	-2.06M	-843K	-3.21M	-1.43M	0
Operating Income+	-11.35M	-12.67M	-18.7M	-25.53M	-42.68M	-26.54M	-25.12M	-27.5M	-42.66M	-56.59M
Operating Margin %	-11.33%	-10.73%	-14.9%	-4.66%	-2.99%	-0.91%	-0.76%	-0.8%	-0.85%	-0.88%
Operating Income Growth %	-0.3%	-0.12%	-0.48%	-0.37%	-0.67%	0.38%	0.05%	-0.1%	-0.55%	-0.33%
EBITDA+	-11.27M	-12.53M	-18.6M	-25.59M	-42.21M	-25.82M	-24.45M	-26.94M	-42.02M	-55.47M
EBITDA Margin %	-11.25%	-10.61%	-14.81%	-4.68%	-2.96%	-0.88%	-0.74%	-0.78%	-0.84%	-0.86%
EBITDA Growth %	-0.3%	-0.11%	-0.48%	-0.38%	-0.65%	0.39%	0.05%	-0.1%	-0.56%	-0.32%
D&A (Non-Cash Add-back)	83.72K	139.7K	105.45K	-63K	465K	715K	673K	568K	632K	1.13M
EBIT	-11.35M	-12.67M	-18.7M	-25.2M	-41.99M	-26.52M	-25.08M	-26.61M	-34.17M	-56.43M
Net Interest Income+	110.34K	110.95K	28.37K	-27K	47.82K	-33K	-29K	23.5K	-1.14M	-5.36M
Interest Income	110.34K	110.95K	28.37K	0	47.82K	0	0	23.5K	0	0
Interest Expense	0	0	0	27K	0	33K	29K	0	1.14M	5.36M
Other Income/Expense	110.34K	110.95K	43.24K	305K	653K	-5K	18K	876K	7.34M	-5.2M
Pretax Income+	-11.24M	-12.56M	-18.66M	-25.22M	-42.03M	-26.55M	-25.1M	-26.63M	-35.31M	-61.79M
Pretax Margin %	-11.22%	-10.64%	-14.86%	-4.61%	-2.95%	-0.91%	-0.76%	-0.77%	-0.7%	-0.96%
Income Tax+	971.88K	1.05M	1.45M	-121K	4K	38K	42K	36K	66K	54K
Effective Tax Rate %	0.91%	0.92%	0.92%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-10.27M	-11.51M	-17.21M	-25.1M	-42.03M	-26.58M	-25.14M	-26.66M	-35.38M	-61.84M
Net Margin %	-10.25%	-9.75%	-13.71%	-4.59%	-2.95%	-0.91%	-0.76%	-0.77%	-0.71%	-0.96%
Net Income Growth %	-0.31%	-0.12%	-0.49%	-0.46%	-0.67%	0.37%	0.05%	-0.06%	-0.33%	-0.75%
Net Income (Continuing)	-	-	-	-25.1M	-42.03M	-26.58M	-25.14M	-26.66M	-35.38M	-61.84M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.06	-1.72	-1.85	-1.12	-3.00	-2.07	-1.03	-1.57	-1.40	-2.39
EPS Growth %	0.08%	0.17%	-0.08%	0.39%	-1.68%	0.31%	0.5%	-0.52%	0.11%	-0.71%
EPS (Basic)	-2.06	-1.72	-1.84	-1.12	-3.00	-2.07	-1.03	-1.57	-1.40	-2.39
Diluted Shares Outstanding	4.99M	6.7M	9.33M	22.33M	20.29M	20.29M	24.36M	25M	25.33M	25.88M
Basic Shares Outstanding	4.99M	6.69M	9.3M	22.33M	20.29M	20.29M	24.36M	25M	25.33M	25.88M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	8.51M	7.28M	22.26M	24.13M	78.39M	121.33M	92.13M	87.46M	104.01M	57M
Cash & Short-Term Investments	4.17M	3.79M	14.82M	20.17M	73.64M	110.75M	85.16M	79.34M	89.06M	35.88M
Cash Only	4.17M	3.79M	14.82M	20.17M	73.64M	110.75M	55.51M	18.16M	22.12M	14.05M
Short-Term Investments	0	0	0	0	0	0	29.65M	61.18M	66.94M	21.84M
Accounts Receivable	659.37K	170.15K	239.81K	1.91M	2.51M	7.88M	3.43M	4.96M	7.92M	11.96M
Days Sales Outstanding	240.19	52.6	69.74	127.42	64.16	98.43	37.87	52.6	57.66	67.96
Inventory	1.37M	1.04M	1.16M	742K	1.13M	1.65M	2.13M	2.13M	5.6M	7.27M
Days Inventory Outstanding	1.25K	748.93	571.5	213.08	138.12	101.05	127.49	128.39	262.54	291.75
Other Current Assets	2.31M	2.28M	6.05M	200K	201K	201K	290K	0	18K	1.88M
Total Non-Current Assets+	94.49K	387.38K	742.09K	1.66M	4.08M	4.17M	23.88M	10.81M	7.63M	22.71M
Property, Plant & Equipment	94.49K	387.38K	742.09K	1.31M	3.71M	2.94M	2.81M	2.05M	4.32M	13.59M
Fixed Asset Turnover	10.60x	3.05x	1.69x	4.18x	3.84x	9.95x	11.77x	16.78x	11.62x	4.73x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	225K	364K	472K	443K	465K	487K	5.57M
Long-Term Investments	0	0	0	0	0	0	19.69M	6.93M	0	0
Other Non-Current Assets	0	0	0	125K	1K	761K	942K	1.36M	2.83M	3.55M
Total Assets+	8.6M	7.67M	23M	25.78M	82.46M	125.5M	116.02M	98.26M	111.64M	79.71M
Asset Turnover	0.12x	0.15x	0.05x	0.21x	0.17x	0.23x	0.28x	0.35x	0.45x	0.81x
Asset Growth %	0.58%	-0.11%	2%	0.12%	2.2%	0.52%	-0.08%	-0.15%	0.14%	-0.29%
Total Current Liabilities+	1.75M	2.55M	3.88M	4.48M	7.71M	7.39M	9.15M	10.69M	13.2M	20.16M
Accounts Payable	1.03M	990.04K	271.73K	1.92M	4.33M	3.12M	2.71M	3M	3.79M	6.29M
Days Payables Outstanding	933.87	714.67	134.45	550.23	531.97	191.43	161.93	181.38	177.95	252.62
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	33K	0
Other Current Liabilities	722.96K	1.56M	3.61M	438K	560K	949K	355K	456K	506K	2.51M
Current Ratio	4.86x	2.86x	5.74x	5.38x	10.17x	16.42x	10.07x	8.18x	7.88x	2.83x
Quick Ratio	4.08x	2.45x	5.44x	5.22x	10.02x	16.20x	9.84x	7.98x	7.46x	2.47x
Cash Conversion Cycle	552.12	86.86	506.79	-209.72	-329.7	8.05	3.42	-0.39	142.25	107.09
Total Non-Current Liabilities+	0	0	134.25K	471K	2.35M	2.46M	2.25M	2.83M	49.38M	55.05M
Long-Term Debt	0	0	134.25K	0	0	0	0	0	39.81M	42.24M
Capital Lease Obligations	0	0	0	0	1.92M	878K	918K	306K	1.7M	2.84M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	42.46K	0	503K	1.33M	1.83M	7.51M	9.64M
Total Liabilities	1.75M	2.55M	4.01M	4.95M	10.06M	9.85M	11.39M	13.52M	62.58M	75.21M
Total Debt+	0	0	134.25K	0	1.92M	878K	1.64M	918K	42.41M	45.98M
Net Debt	-4.17M	-3.79M	-14.68M	-20.17M	-71.72M	-109.87M	-53.87M	-17.25M	20.29M	31.93M
Debt / Equity	-	-	0.01x	-	0.03x	0.01x	0.02x	0.01x	0.86x	10.22x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-945.48x	-	-804.24x	-866.14x	-	-37.32x	-10.56x
Total Equity+	6.85M	5.12M	18.99M	20.83M	72.4M	115.66M	104.62M	84.74M	49.06M	4.5M
Equity Growth %	0.63%	-0.25%	2.71%	0.1%	2.48%	0.6%	-0.1%	-0.19%	-0.42%	-0.91%
Book Value per Share	1.37	0.76	2.04	0.93	3.57	5.70	4.30	3.39	1.94	0.17
Total Shareholders' Equity	6.85M	5.12M	18.99M	20.83M	72.4M	115.66M	104.62M	84.74M	49.06M	4.5M
Common Stock	126.26M	134.81M	162.69M	3K	3K	3K	3K	3K	3K	3K
Retained Earnings	-121.11M	-132.22M	-148.49M	-152.83M	-194.91M	-221.5M	-235.92M	-262.59M	-297.97M	-359.81M
Treasury Stock	-	-	-	0	-	-	0	-	0	0
Accumulated OCI	1.7M	2.53M	4.79M	8.18M	8.15M	8.26M	8.06M	7.63M	-1.89M	-1.94M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.93M	-6.58M	-9.54M	-19.25M	-22.75M	-25.9M	-18.04M	-19.09M	-38.01M	-48.94M
Operating CF Margin %	-5.92%	-5.57%	-7.6%	-3.52%	-1.59%	-0.89%	-0.55%	-0.55%	-0.76%	-0.76%
Operating CF Growth %	-0.22%	-0.11%	-0.45%	-1.02%	-0.18%	-0.14%	0.3%	-0.06%	-0.99%	-0.29%
Net Income	-5.81M	-8.85M	-9.37M	-25.1M	-42.03M	-26.58M	-25.14M	-26.66M	-35.38M	-61.84M
Depreciation & Amortization	62.52K	107.35K	80.97K	269K	465K	715K	969K	568K	632K	1.13M
Stock-Based Compensation	0	1.22M	0	1.95M	16.59M	5.66M	6.33M	7M	8.38M	13.5M
Deferred Taxes	0	0	0	-129K	0	0	0	0	0	0
Other Non-Cash Items	377.79K	0	365.1K	494K	895K	1.66M	1.53M	1.21M	-5.07M	2.96M
Working Capital Changes	-560.2K	942.55K	-611.68K	3.27M	1.33M	-7.36M	-1.73M	-1.2M	-6.57M	-4.68M
Change in Receivables	-385.38K	-37.68K	-1.39M	1.97M	-582K	-4.98M	-1.19M	-985K	-3.3M	-4.17M
Change in Inventory	-579.58K	256K	-69.19K	17K	-468K	-745K	-144K	-371K	-3.69M	-2.16M
Change in Payables	0	0	0	69K	2.31M	-1.33M	0	282K	809K	340K
Cash from Investing+	0	0	-268.67K	0	-847K	-1.17M	-50.21M	-19.33M	1.61M	37.36M
Capital Expenditures	0	0	-268.67K	0	-590K	-894K	-487K	-452K	-1.38M	-9.17M
CapEx % of Revenue	-	-	0.21%	-	0.04%	0.03%	0.01%	0.01%	0.03%	0.14%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	-257K	-280K	-49.72M	-73K	-66K	-162K
Cash from Financing+	0	0	15.67M	0	77.06M	64.05M	64.06M	900K	40.37M	3.51M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	-1.06M	0	-4.6M	-5.05M	64.08M	900K	1.61M	3.51M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	0	0	-9.81M	0	-23.59M	-27.07M	-18.52M	-19.61M	-39.46M	-58.27M
FCF Margin %	-	-	-7.81%	-	-1.65%	-0.93%	-0.56%	-0.57%	-0.79%	-0.91%
FCF Growth %	1%	-	-	1%	-	-0.15%	0.32%	-0.06%	-1.01%	-0.48%
FCF per Share	-	-	-1.05	-	-1.16	-1.33	-0.76	-0.78	-1.56	-2.25
FCF Conversion (FCF/Net Income)	0.58x	0.57x	0.55x	0.77x	0.54x	0.97x	0.72x	0.72x	1.07x	0.79x
Interest Paid	-	-	-	27K	42K	3K	29K	15K	1.14M	5.36M
Taxes Paid	-	-	-	0	-	42K	0	17K	44K	41K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-185.59%	-192.26%	-142.74%	-126.08%	-90.16%	-28.27%	-22.83%	-28.16%	-52.89%	-230.96%
Return on Invested Capital (ROIC)	-433.26%	-473.71%	-497.63%	-771.47%	-4788.22%	-615.68%	-66.64%	-34.89%	-46.76%	-80.25%
Gross Margin	59.92%	57.17%	41.23%	76.78%	79.16%	79.65%	81.52%	82.45%	84.48%	85.85%
Net Margin	-1025.14%	-974.99%	-1370.83%	-458.57%	-294.68%	-90.94%	-76.13%	-77.47%	-70.56%	-96.26%
Debt / Equity	-	-	0.01x	-	0.03x	0.01x	0.02x	0.01x	0.86x	10.22x
Interest Coverage	-	-	-	-945.48x	-	-804.24x	-866.14x	-	-37.32x	-10.56x
FCF Conversion	0.58x	0.57x	0.55x	0.77x	0.54x	0.97x	0.72x	0.72x	1.07x	0.79x
Revenue Growth	1.66%	17.83%	6.31%	336.12%	160.56%	104.95%	12.98%	4.23%	45.68%	28.14%

Revenue by Segment

	2019	2020	2022	2023	2024
Lease Revenue	-	-	-	-	358K
Lease Revenue Growth	-	-	-	-	-
Foreign	292K	-	160K	-	-
Foreign Growth	-	-	-	-	-
Recell System	-	435K	-	-	-
Recell System Growth	-	-	-	-	-

Revenue by Geography

	2019	2020	2022	2023	2024
UNITED STATES	13.8M	28.95M	33.26M	46.36M	62.16M
UNITED STATES Growth	-	109.82%	14.86%	39.40%	34.08%
JAPAN	-	-	-	3.37M	1.43M
JAPAN Growth	-	-	-	-	-57.54%
AUSTRALIA	-	-	-	222K	312K
AUSTRALIA Growth	-	-	-	-	40.54%
European Union	-	-	-	51K	155K
European Union Growth	-	-	-	-	203.92%

Frequently Asked Questions

Growth & Financials

AVITA Medical, Inc. (RCEL) reported $74.9M in revenue for fiscal year 2024. This represents a 2134% increase from $3.4M in 2011.

AVITA Medical, Inc. (RCEL) grew revenue by 28.1% over the past year. This is strong growth.

AVITA Medical, Inc. (RCEL) reported a net loss of $51.6M for fiscal year 2024.

Dividend & Returns

AVITA Medical, Inc. (RCEL) has a return on equity (ROE) of -231.0%. Negative ROE indicates the company is unprofitable.

AVITA Medical, Inc. (RCEL) had negative free cash flow of $42.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

AVITA Medical, Inc. (RCEL) 10-Year Financial Performance & Capital Metrics

RCEL • • Industrial / General

HealthcareMedical DevicesAesthetic & Reconstructive DevicesBreast Implants & Aesthetic Devices

Revenue $64M +28.1%
EBITDA -$55M -32.0%
Net Income -$62M -74.8%
EPS (Diluted) -2.39 -70.7%
Gross Margin 85.85% +1.6%
EBITDA Margin -86.33% -3.0%
Operating Margin -88.08% -3.5%
Net Margin -96.26% -36.4%
ROE -230.96% -336.7%
ROIC -80.25% -71.6%
Debt/Equity 10.22 +1082.3%
Interest Coverage -10.56 +71.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 35.1%

✗Weaknesses

✗High debt to equity ratio of 10.2x
✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 10 (bottom 10%)
✗Trading more than 30% below 52-week high
✗Expensive at 19.9x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y51.85%

5Y35.12%

3Y24.84%

TTM38.32%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-3.5%

EPS CAGR

10Y-

5Y-

3Y-

TTM7.81%

ROCE

10Y Avg-98.19%

5Y Avg-39.13%

3Y Avg-48.6%

Latest-71.64%

Peer Comparison

Breast Implants & Aesthetic Devices

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INMDInMode Ltd.	888.09M	14.05	6.24	-19.76%	41.04%	22.89%	14.86%	0.01
RCELAVITA Medical, Inc.	105.51M	3.46	-1.45	28.14%	-68.87%	-230.96%		10.22
SSKNSTRATA Skin Sciences, Inc.	7.6M	1.29	-4.96	0.61%	-35.64%	-8.4%		3.31
ESTAEstablishment Labs Holdings Inc.	1.92B	65.96	-21.99	0.53%	-43.45%	-5.07%		4.24

Profit & Loss

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1M	1.18M	1.26M	5.47M	14.26M	29.23M	33.02M	34.42M	50.14M	64.25M
Revenue Growth %	0.02%	0.18%	0.06%	3.36%	1.61%	1.05%	0.13%	0.04%	0.46%	0.28%
Cost of Goods Sold+	401.57K	505.64K	737.7K	1.27M	2.97M	5.95M	6.1M	6.04M	7.78M	9.09M
COGS % of Revenue	0.4%	0.43%	0.59%	0.23%	0.21%	0.2%	0.18%	0.18%	0.16%	0.14%
Gross Profit+	600.44K	675K	517.47K	4.2M	11.29M	23.28M	26.92M	28.38M	42.36M	55.16M
Gross Margin %	0.6%	0.57%	0.41%	0.77%	0.79%	0.8%	0.82%	0.82%	0.84%	0.86%
Gross Profit Growth %	-0.14%	0.12%	-0.23%	7.12%	1.69%	1.06%	0.16%	0.05%	0.49%	0.3%
Operating Expenses+	11.95M	13.35M	19.15M	29.73M	53.97M	49.82M	52.04M	55.88M	85.02M	111.75M
OpEx % of Revenue	11.93%	11.3%	15.25%	5.43%	3.78%	1.7%	1.58%	1.62%	1.7%	1.74%
Selling, General & Admin	10.93M	13.9M	21.21M	27.65M	48.73M	37.06M	37.21M	45.24M	65.63M	91.39M
SG&A % of Revenue	10.91%	11.78%	16.9%	5.05%	3.42%	1.27%	1.13%	1.31%	1.31%	1.42%
Research & Development	3.46M	6.27M	8.45M	8M	9.16M	14.82M	15.67M	13.86M	20.82M	20.36M
R&D % of Revenue	3.45%	5.31%	6.74%	1.46%	0.64%	0.51%	0.47%	0.4%	0.42%	0.32%
Other Operating Expenses	0	0	0	-5.92M	-3.93M	-2.06M	-843K	-3.21M	-1.43M	0
Operating Income+	-11.35M	-12.67M	-18.7M	-25.53M	-42.68M	-26.54M	-25.12M	-27.5M	-42.66M	-56.59M
Operating Margin %	-11.33%	-10.73%	-14.9%	-4.66%	-2.99%	-0.91%	-0.76%	-0.8%	-0.85%	-0.88%
Operating Income Growth %	-0.3%	-0.12%	-0.48%	-0.37%	-0.67%	0.38%	0.05%	-0.1%	-0.55%	-0.33%
EBITDA+	-11.27M	-12.53M	-18.6M	-25.59M	-42.21M	-25.82M	-24.45M	-26.94M	-42.02M	-55.47M
EBITDA Margin %	-11.25%	-10.61%	-14.81%	-4.68%	-2.96%	-0.88%	-0.74%	-0.78%	-0.84%	-0.86%
EBITDA Growth %	-0.3%	-0.11%	-0.48%	-0.38%	-0.65%	0.39%	0.05%	-0.1%	-0.56%	-0.32%
D&A (Non-Cash Add-back)	83.72K	139.7K	105.45K	-63K	465K	715K	673K	568K	632K	1.13M
EBIT	-11.35M	-12.67M	-18.7M	-25.2M	-41.99M	-26.52M	-25.08M	-26.61M	-34.17M	-56.43M
Net Interest Income+	110.34K	110.95K	28.37K	-27K	47.82K	-33K	-29K	23.5K	-1.14M	-5.36M
Interest Income	110.34K	110.95K	28.37K	0	47.82K	0	0	23.5K	0	0
Interest Expense	0	0	0	27K	0	33K	29K	0	1.14M	5.36M
Other Income/Expense	110.34K	110.95K	43.24K	305K	653K	-5K	18K	876K	7.34M	-5.2M
Pretax Income+	-11.24M	-12.56M	-18.66M	-25.22M	-42.03M	-26.55M	-25.1M	-26.63M	-35.31M	-61.79M
Pretax Margin %	-11.22%	-10.64%	-14.86%	-4.61%	-2.95%	-0.91%	-0.76%	-0.77%	-0.7%	-0.96%
Income Tax+	971.88K	1.05M	1.45M	-121K	4K	38K	42K	36K	66K	54K
Effective Tax Rate %	0.91%	0.92%	0.92%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-10.27M	-11.51M	-17.21M	-25.1M	-42.03M	-26.58M	-25.14M	-26.66M	-35.38M	-61.84M
Net Margin %	-10.25%	-9.75%	-13.71%	-4.59%	-2.95%	-0.91%	-0.76%	-0.77%	-0.71%	-0.96%
Net Income Growth %	-0.31%	-0.12%	-0.49%	-0.46%	-0.67%	0.37%	0.05%	-0.06%	-0.33%	-0.75%
Net Income (Continuing)	-	-	-	-25.1M	-42.03M	-26.58M	-25.14M	-26.66M	-35.38M	-61.84M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.06	-1.72	-1.85	-1.12	-3.00	-2.07	-1.03	-1.57	-1.40	-2.39
EPS Growth %	0.08%	0.17%	-0.08%	0.39%	-1.68%	0.31%	0.5%	-0.52%	0.11%	-0.71%
EPS (Basic)	-2.06	-1.72	-1.84	-1.12	-3.00	-2.07	-1.03	-1.57	-1.40	-2.39
Diluted Shares Outstanding	4.99M	6.7M	9.33M	22.33M	20.29M	20.29M	24.36M	25M	25.33M	25.88M
Basic Shares Outstanding	4.99M	6.69M	9.3M	22.33M	20.29M	20.29M	24.36M	25M	25.33M	25.88M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	8.51M	7.28M	22.26M	24.13M	78.39M	121.33M	92.13M	87.46M	104.01M	57M
Cash & Short-Term Investments	4.17M	3.79M	14.82M	20.17M	73.64M	110.75M	85.16M	79.34M	89.06M	35.88M
Cash Only	4.17M	3.79M	14.82M	20.17M	73.64M	110.75M	55.51M	18.16M	22.12M	14.05M
Short-Term Investments	0	0	0	0	0	0	29.65M	61.18M	66.94M	21.84M
Accounts Receivable	659.37K	170.15K	239.81K	1.91M	2.51M	7.88M	3.43M	4.96M	7.92M	11.96M
Days Sales Outstanding	240.19	52.6	69.74	127.42	64.16	98.43	37.87	52.6	57.66	67.96
Inventory	1.37M	1.04M	1.16M	742K	1.13M	1.65M	2.13M	2.13M	5.6M	7.27M
Days Inventory Outstanding	1.25K	748.93	571.5	213.08	138.12	101.05	127.49	128.39	262.54	291.75
Other Current Assets	2.31M	2.28M	6.05M	200K	201K	201K	290K	0	18K	1.88M
Total Non-Current Assets+	94.49K	387.38K	742.09K	1.66M	4.08M	4.17M	23.88M	10.81M	7.63M	22.71M
Property, Plant & Equipment	94.49K	387.38K	742.09K	1.31M	3.71M	2.94M	2.81M	2.05M	4.32M	13.59M
Fixed Asset Turnover	10.60x	3.05x	1.69x	4.18x	3.84x	9.95x	11.77x	16.78x	11.62x	4.73x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	225K	364K	472K	443K	465K	487K	5.57M
Long-Term Investments	0	0	0	0	0	0	19.69M	6.93M	0	0
Other Non-Current Assets	0	0	0	125K	1K	761K	942K	1.36M	2.83M	3.55M
Total Assets+	8.6M	7.67M	23M	25.78M	82.46M	125.5M	116.02M	98.26M	111.64M	79.71M
Asset Turnover	0.12x	0.15x	0.05x	0.21x	0.17x	0.23x	0.28x	0.35x	0.45x	0.81x
Asset Growth %	0.58%	-0.11%	2%	0.12%	2.2%	0.52%	-0.08%	-0.15%	0.14%	-0.29%
Total Current Liabilities+	1.75M	2.55M	3.88M	4.48M	7.71M	7.39M	9.15M	10.69M	13.2M	20.16M
Accounts Payable	1.03M	990.04K	271.73K	1.92M	4.33M	3.12M	2.71M	3M	3.79M	6.29M
Days Payables Outstanding	933.87	714.67	134.45	550.23	531.97	191.43	161.93	181.38	177.95	252.62
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	33K	0
Other Current Liabilities	722.96K	1.56M	3.61M	438K	560K	949K	355K	456K	506K	2.51M
Current Ratio	4.86x	2.86x	5.74x	5.38x	10.17x	16.42x	10.07x	8.18x	7.88x	2.83x
Quick Ratio	4.08x	2.45x	5.44x	5.22x	10.02x	16.20x	9.84x	7.98x	7.46x	2.47x
Cash Conversion Cycle	552.12	86.86	506.79	-209.72	-329.7	8.05	3.42	-0.39	142.25	107.09
Total Non-Current Liabilities+	0	0	134.25K	471K	2.35M	2.46M	2.25M	2.83M	49.38M	55.05M
Long-Term Debt	0	0	134.25K	0	0	0	0	0	39.81M	42.24M
Capital Lease Obligations	0	0	0	0	1.92M	878K	918K	306K	1.7M	2.84M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	42.46K	0	503K	1.33M	1.83M	7.51M	9.64M
Total Liabilities	1.75M	2.55M	4.01M	4.95M	10.06M	9.85M	11.39M	13.52M	62.58M	75.21M
Total Debt+	0	0	134.25K	0	1.92M	878K	1.64M	918K	42.41M	45.98M
Net Debt	-4.17M	-3.79M	-14.68M	-20.17M	-71.72M	-109.87M	-53.87M	-17.25M	20.29M	31.93M
Debt / Equity	-	-	0.01x	-	0.03x	0.01x	0.02x	0.01x	0.86x	10.22x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-945.48x	-	-804.24x	-866.14x	-	-37.32x	-10.56x
Total Equity+	6.85M	5.12M	18.99M	20.83M	72.4M	115.66M	104.62M	84.74M	49.06M	4.5M
Equity Growth %	0.63%	-0.25%	2.71%	0.1%	2.48%	0.6%	-0.1%	-0.19%	-0.42%	-0.91%
Book Value per Share	1.37	0.76	2.04	0.93	3.57	5.70	4.30	3.39	1.94	0.17
Total Shareholders' Equity	6.85M	5.12M	18.99M	20.83M	72.4M	115.66M	104.62M	84.74M	49.06M	4.5M
Common Stock	126.26M	134.81M	162.69M	3K	3K	3K	3K	3K	3K	3K
Retained Earnings	-121.11M	-132.22M	-148.49M	-152.83M	-194.91M	-221.5M	-235.92M	-262.59M	-297.97M	-359.81M
Treasury Stock	-	-	-	0	-	-	0	-	0	0
Accumulated OCI	1.7M	2.53M	4.79M	8.18M	8.15M	8.26M	8.06M	7.63M	-1.89M	-1.94M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.93M	-6.58M	-9.54M	-19.25M	-22.75M	-25.9M	-18.04M	-19.09M	-38.01M	-48.94M
Operating CF Margin %	-5.92%	-5.57%	-7.6%	-3.52%	-1.59%	-0.89%	-0.55%	-0.55%	-0.76%	-0.76%
Operating CF Growth %	-0.22%	-0.11%	-0.45%	-1.02%	-0.18%	-0.14%	0.3%	-0.06%	-0.99%	-0.29%
Net Income	-5.81M	-8.85M	-9.37M	-25.1M	-42.03M	-26.58M	-25.14M	-26.66M	-35.38M	-61.84M
Depreciation & Amortization	62.52K	107.35K	80.97K	269K	465K	715K	969K	568K	632K	1.13M
Stock-Based Compensation	0	1.22M	0	1.95M	16.59M	5.66M	6.33M	7M	8.38M	13.5M
Deferred Taxes	0	0	0	-129K	0	0	0	0	0	0
Other Non-Cash Items	377.79K	0	365.1K	494K	895K	1.66M	1.53M	1.21M	-5.07M	2.96M
Working Capital Changes	-560.2K	942.55K	-611.68K	3.27M	1.33M	-7.36M	-1.73M	-1.2M	-6.57M	-4.68M
Change in Receivables	-385.38K	-37.68K	-1.39M	1.97M	-582K	-4.98M	-1.19M	-985K	-3.3M	-4.17M
Change in Inventory	-579.58K	256K	-69.19K	17K	-468K	-745K	-144K	-371K	-3.69M	-2.16M
Change in Payables	0	0	0	69K	2.31M	-1.33M	0	282K	809K	340K
Cash from Investing+	0	0	-268.67K	0	-847K	-1.17M	-50.21M	-19.33M	1.61M	37.36M
Capital Expenditures	0	0	-268.67K	0	-590K	-894K	-487K	-452K	-1.38M	-9.17M
CapEx % of Revenue	-	-	0.21%	-	0.04%	0.03%	0.01%	0.01%	0.03%	0.14%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	-257K	-280K	-49.72M	-73K	-66K	-162K
Cash from Financing+	0	0	15.67M	0	77.06M	64.05M	64.06M	900K	40.37M	3.51M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	-1.06M	0	-4.6M	-5.05M	64.08M	900K	1.61M	3.51M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	0	0	-9.81M	0	-23.59M	-27.07M	-18.52M	-19.61M	-39.46M	-58.27M
FCF Margin %	-	-	-7.81%	-	-1.65%	-0.93%	-0.56%	-0.57%	-0.79%	-0.91%
FCF Growth %	1%	-	-	1%	-	-0.15%	0.32%	-0.06%	-1.01%	-0.48%
FCF per Share	-	-	-1.05	-	-1.16	-1.33	-0.76	-0.78	-1.56	-2.25
FCF Conversion (FCF/Net Income)	0.58x	0.57x	0.55x	0.77x	0.54x	0.97x	0.72x	0.72x	1.07x	0.79x
Interest Paid	-	-	-	27K	42K	3K	29K	15K	1.14M	5.36M
Taxes Paid	-	-	-	0	-	42K	0	17K	44K	41K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-185.59%	-192.26%	-142.74%	-126.08%	-90.16%	-28.27%	-22.83%	-28.16%	-52.89%	-230.96%
Return on Invested Capital (ROIC)	-433.26%	-473.71%	-497.63%	-771.47%	-4788.22%	-615.68%	-66.64%	-34.89%	-46.76%	-80.25%
Gross Margin	59.92%	57.17%	41.23%	76.78%	79.16%	79.65%	81.52%	82.45%	84.48%	85.85%
Net Margin	-1025.14%	-974.99%	-1370.83%	-458.57%	-294.68%	-90.94%	-76.13%	-77.47%	-70.56%	-96.26%
Debt / Equity	-	-	0.01x	-	0.03x	0.01x	0.02x	0.01x	0.86x	10.22x
Interest Coverage	-	-	-	-945.48x	-	-804.24x	-866.14x	-	-37.32x	-10.56x
FCF Conversion	0.58x	0.57x	0.55x	0.77x	0.54x	0.97x	0.72x	0.72x	1.07x	0.79x
Revenue Growth	1.66%	17.83%	6.31%	336.12%	160.56%	104.95%	12.98%	4.23%	45.68%	28.14%

Revenue by Segment

	2019	2020	2022	2023	2024
Lease Revenue	-	-	-	-	358K
Lease Revenue Growth	-	-	-	-	-
Foreign	292K	-	160K	-	-
Foreign Growth	-	-	-	-	-
Recell System	-	435K	-	-	-
Recell System Growth	-	-	-	-	-

Revenue by Geography

	2019	2020	2022	2023	2024
UNITED STATES	13.8M	28.95M	33.26M	46.36M	62.16M
UNITED STATES Growth	-	109.82%	14.86%	39.40%	34.08%
JAPAN	-	-	-	3.37M	1.43M
JAPAN Growth	-	-	-	-	-57.54%
AUSTRALIA	-	-	-	222K	312K
AUSTRALIA Growth	-	-	-	-	40.54%
European Union	-	-	-	51K	155K
European Union Growth	-	-	-	-	203.92%

Frequently Asked Questions

Growth & Financials

AVITA Medical, Inc. (RCEL) reported $74.9M in revenue for fiscal year 2024. This represents a 2134% increase from $3.4M in 2011.

AVITA Medical, Inc. (RCEL) grew revenue by 28.1% over the past year. This is strong growth.

AVITA Medical, Inc. (RCEL) reported a net loss of $51.6M for fiscal year 2024.

Dividend & Returns

AVITA Medical, Inc. (RCEL) has a return on equity (ROE) of -231.0%. Negative ROE indicates the company is unprofitable.

AVITA Medical, Inc. (RCEL) had negative free cash flow of $42.0M in fiscal year 2024, likely due to heavy capital investments.